Canada court dismissed Zantac litigation: GSK
Bengaluru: The British Columbia Supreme Court dismissed a proposed class action in Canada against heartburn drug Zantac over increased cancer risk, drugmaker GSK Plc said on Friday.
First approved in 1983, Zantac became the world's best selling medicine in 1988 and one of the first drugs to top $1 billion in annual sales.
Originally marketed by a forerunner of GSK, it was later sold successively to Pfizer, Boehringer Ingelheim and finally Sanofi. All four drugmakers, citing scientific consensus, have repeatedly asserted that Zantac does not cause cancer, ahead of an upcoming US trial for GSK.
"GSK will continue to vigorously defend proposed class actions by ranitidine users that have been filed in Ontario and Quebec as well as individual actions filed by ranitidine users in Canada," the British company said in a statement on Friday, adding it welcomed the decision.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd